Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AND019 |
Synonyms | |
Therapy Description |
AND019 is a selective estrogen receptor degrader (SERD) that may inhibit growth of ESR1 (ER alpha)-positive tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AND019 | AND-019|AND 019 | Hormone - Anti-estrogens 29 | AND019 is a selective estrogen receptor degrader (SERD) that may inhibit growth of ESR1 (ER alpha)-positive tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05187832 | Phase I | AND019 | A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer | Recruiting | USA | 0 |